NASDAQ: FEMY - Femasys Inc.

Rentabilität für sechs Monate: +16.22%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Femasys Inc.


Über das Unternehmen Femasys Inc.

Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally.

weitere details
The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. In addition, the company provides non-surgical product technologies. It offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

IPO date 2021-06-18
ISIN US31447E1055
Industry Health Care Equipment & Supplies
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.femasys.com
Цена ао 1.52
Preisänderung pro Tag: -3.37% (1.335)
Preisänderung pro Woche: -19.38% (1.6)
Preisänderung pro Monat: -21.82% (1.65)
Preisänderung über 3 Monate: +14.16% (1.13)
Preisänderung über sechs Monate: +16.22% (1.11)
Preisänderung pro Jahr: -16.77% (1.55)
Preisänderung über 3 Jahre: -45.11% (2.35)
Preisänderung seit Jahresbeginn: +14.16% (1.13)

Unterschätzung

Name Bedeutung Grad
P/S 13.28 1
P/BV 0.7754 9
P/E 0 0
EV/EBITDA 0.0577 10
Gesamt: 5

Effizienz

Name Bedeutung Grad
ROA, % -51.33 0
ROE, % -77.63 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.343 10
Gesamt: 9.6

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 15.39 3
Rentabilität Ebitda, % 29.11 4
Rentabilität EPS, % -25.6 0
Gesamt: 2.2



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Dov Elefant Chief Financial Officer 595.14k 1967 (58 Jahre)
Mr. Daniel Scott Currie COO, Senior VP & Secretary 548.15k 1964 (61 Jahr)
Ms. Mary An Merchant J.D., Ph.D. Vice President of Counsel & Intellectual Property N/A
Dr. Jeffrey Marcus M.D., M.S. Chief Medical Advisor N/A
Ms. Christine Thomas Senior VP of Regulatory & Clinical Affairs N/A 1973 (52 Jahr)
Dr. James H. Liu M.D. Chief Medical Officer N/A
Mr. Richard Spector Chief Commercial Officer N/A 1971 (54 Jahr)
Ms. Kathy Lee-Sepsick M.B.A. Founder, President, CEO & Director 804.67k 1968 (57 Jahre)
Ms. Sue Owens Vice President of Sales
Ms. Naomi Phaneuf Vice President of Marketing

Adresse: United States, Suwanee. GA, 3950 Johns Creek Court - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.femasys.com